Clodronate decreases the frequency of skeletal metastases in women with breast cancer

Bone

Volumn 19, Issue 6, 1996, Pages 663-667

  Kanis, J A ^a   Powles, T ^b   Paterson, A H G ^c   McCloskey, E V ^a   Ashley, S ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c TOM BAKER CANCER CENTRE   (Canada)

Author keywords

Breast cancer; Clodronate; Fracture; Metastatic bone disease

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; BREAST CANCER; CANADA; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FRACTURE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MORBIDITY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM; VERTEBRA FRACTURE; VERTEBRA MALFORMATION; X RAY FILM;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, NON-NARCOTIC; BONE NEOPLASMS; BREAST NEOPLASMS; CLODRONIC ACID; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; SURVIVAL RATE;

EID: 0030474026     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(96)00285-2     Document Type: Article

References (31)

1. 1. Belch, A. R., Bergsagel, D. E., Wilson, K., O'Reilly, S., Wilson, J., Sutton, D., Pater, J., Johnston, D., and Zee, B. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 9:1397-1402; 1991.
2. 2. Biermann, W. A., Cantor, R. I., Fellin, F. M., Jakobowski, J., Hopkins, L., and Newbold, R. C. An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast Bone 12(suppl 1):37-42; 1991.
3. 3. Breast Cancer Task Force. Treatment Committee. National Cancer Institute, Breast Cancer. Suggested protocol guidelines for combination chemotherapy trials and for combined modality trials. Publication no. (NIH) 77-1192; Washington, DC: U.S. Department of Health, Education and Welfare; 1977.
4. 4. Dunn, C. J., Fitton, A., and Sorkin, E. M. Etidronic acid: A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs Aging 5:446-474; 1994.
5. 5. Elomaa, I., Blomqvist, C., Porkka, L., Lamberg-Allardt, C., and Borgstrom, G. H. Treatment of skeletal disease in breast cancer: A controlled clodronate trial. Bone 8(suppl);53-56; 1987.
6. 6. Elomaa, I., Blomqvist, C., Grohn, P., Porkka, L., Kairento, A. L., Selander, K., Lamberg-Allardt, C., and Holmstrom, T. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet i:146-149; 1983.
7. 7. Ernst, D. S., MacDonald, N., Paterson, A. H. G., Jenson, J., Brasher, P., and Bruera, E. A double-blind crossover trial of intravenous clodronate in metastatic bone pain. J Pain Symptom Management 7:4-11; 1992.
8. 8. Filipponi, P., Cristallini, S., Rizzello, E., Policani, G., Fedeli, L., Gregorio, F., Boldrini, S., Troiani, S., and Massoni, C. Cyclical intravenous clodronate in postmenopausal osteoporosis: Results of a long-term clinical trial. Bone 18:179-184; 1996.
9. 9. Fleisch, H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 42:919-944; 1991.
10. 10. Guise, T. A., Taylor, S. D., Yoneda, T., Sasaki, A., Wright, A., Boyce, B. F., Chirgwin, J. M., and Mundy, G. R. Parathyroid hormone-related protein (PTHrP) expression by breast cancer cells enhance osteolytic bone metastases in vivo. J Bone Miner Res 9(suppl 1):S128; 1994.
11. 11. Galasko, C. S. B. Pathological fractures secondary to metastatic cancer. J Royal Coll Surg (Edin) 19:351-362; 1974.
12. 12. Galasko, C. S. B. The role of the orthopaedic surgeon in the treatment of bone pain. Cancer Surveys 7:103-125; 1988.
13. 13. Hayward, J. L., Meakin, J. W., and Stewart, H. J. Assessment of response and recurrence in breast cancer. Semin Oncol 5:445-449; 1978.
14. 14. Kanis, J. A. and McCloskey, E. V. The use of clodronate in disorders of calcium and skeletal metabolism. Prog Basic Clin Pharmacol 4:89-136; 1990.
15. 15. Kanis, J. A., O'Rourke, N., and McCloskey, E. V. Consequences of neoplasia induced bone resorption and the use of clodronate. Int J Oncol 5:713-731; 1994.
16. 16. Kanis, J. A. and Yates, A. J. P. Measuring serum calcium. BMJ 290:728-729; 1985.
17. 17. McCloskey, E. V., Spector, T. D., Eyres, K. S., Fern, D. E., O'Rourke, N., Vasikaran, S., and Kanis, J. A. The assessment of vertebral deformity - a method for use in population studies and clinical trials. Osteopor Int 3:138-147; 1993.
18. 18. Muggia, F. M. Overview of cancer related hypercalcaemia: Epidemiology and etiology. Sem Oncol 17(suppl 5);3-9; 1990.
19. 19. Orloff, J. J., Wu, T. L., and Stewart, A. F. Parathyroid hormone-like proteins: Biochemical responses and receptor interactions. Endocrin Rev 10:476-495; 1989.
20. 20. Paterson, A. H. G., Powles, T. J., Kanis, J. A., McCloskey, E., Hanson, J., and Ashley, S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59-65; 1993.
21. 21. Powell, G. J., Southby, J., Danks, J. A. et al. Localisation of parathyroid hormone-related protein in breast cancer metastases: Increased incidence in bone compared with other sites. Cancer Res 51:3059-3061; 1991.
22. 22. Ralston, S. H., Gallacher, S. J., Patel, U., Dryburgh, F. J., Frazer, W. D., Cowan, R. A., and Boyle, I. T. Comparison of three intravenous bisphosphonates in cancer associated hypercalcaemia. Lancet ii:1180-1182; 1989.
23. 23. Bundred, N. J., Walker, R. A., Ratcliffe, W. A., Warwick, J., Morrison, J. M., and Ratcliffe, J. G. Parathyroid hormone related protein and skeletal morbidity in breast cancer. Eur J Cancer 28:690-692; 1992.
24. 24. Ryzen, B., Martodam, R. R., Troxell, M., Benson, A., Paterson, A. H. G., Shepard, D., and Hicks, R. Intravenous etidronate in the management of malignant hypercalcemia. Arch Int Med 145:449-452; 1985.
25. 25. Spector, T. D., McCloskey, E., Doyle, D. V., and Kanis, J. A. Prevalence of vertebral fractures in women and the relationship with bone density and symptoms. The Chingford study. J Bone Miner Res 8:817-822; 1993.
26. 26. Taube, T., Elomaa, I., Blomqvist, C., Beneton, M. N. C., and Kanis, J. A. Comparative effects of clodronate and calcitonin in metastatic breast cancer. Eur J Clin Oncol 29:1677-1681; 1993.
27. 27. Taube, T., Elomaa, I., Blomqvist, C., Beneton, M. N. C., and Kanis, J. A. Histomorphometric evidence for osteodast mediated bone resorption in metastatic breast cancer. Bone 15:161-166; 1994.
28. 28. Thiebaud, D., Jaeger, P., and Burckhardt, P. Response to retreatment of malignant hypercalcaemia with the bisphosphonate AHPrBP (APD): Respective role of kidney and bone. J Bone Miner Res 5:221-226; 1990.
29. 29. Thurlimann, B., Waldburger, R., Thiebaud, D., and Seen, H. J. Plicamycin and pamidronate in symptomatic tumour-related hypercalcemia: A prospective randomised crossover trial. Ann Oncol 3:619-623; 1992.
30. 30. Van Holten-Verzantvoort, A. T., Bijvoet, O. L. M., Hermans, J., Harink, H. I. J., Elte, J. W. K., Beex, L. V. A. M., Cletout, F. J., Kroom, H. M., Vermij, P., Neijt, J. P., and Blijham, G. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet ii:983-985; 1987.
31. 31. Van Holten-Verzantvoort, A. T. M., Kroon, H. M , Bijvoet, O. L. M., Cleton, F. J., Beex, L. V. A. M., Blijham, G., Hermans, J., Neijt, J. P., Papapoulos, S. E., and Sleeboom, H. P. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 11:491-498; 1993.